Carcinosarcoma of the prostate: Report of 21 cases

P. A. Dundore, J. C. Cheville, A. G. Nascimento, G. M. Farrow, D. G. Bostwick

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Background. Carcinosarcoma of the prostate is an unusual malignancy characterized by adenocarcinoma intimately admixed with sarcoma. Methods. The authors reviewed the clinical and pathologic findings of 21 cases of carcinosarcoma of the prostate from the files of the Mayo Clinic. Results. Patient age ranged from 50 to 89 years (mean, 68 years). Ten patients (48%) had a previous diagnosis of prostatic acinar adenocarcinoma 2-73 months (mean, 33 months) before the diagnosis of carcinosarcoma, 8 of whom had received androgen deprivation therapy and/or radiation therapy in the interim. The Gleason score of adenocarcinoma ranged from 7 to 10 (mean, 9; median, 9). The sarcomas consisted of osteosarcoma (13), leiomyosarcoma (5), fibrosarcoma (1), malignant fibrous histiocytoma (1), and rhabdomyosarcoma (1), and the grade of the sarcoma component ranged from 2 to 4 (mean, 4; median, 4). Adenocarcinoma was the dominant histologic pattern in 7 cases and sarcoma in 14. Immunohistochemical staining revealed cytoplasmic reactivity for prostate specific antigen or keratin in 16 of 16 cases in the adenocarcinoma component. The sarcoma component was positive for vimentin in 16 of 16 cases, actin in 8 of 16 (focal in 2), S-100 protein in 2 of 16, and desmin in 1 of 16. At the time of diagnosis of carcinosarcoma, 11 patients had metastases, including 4 with metastatic adenocarcinoma before the diagnosis of carcinosarcoma. Treatment varied, and nonsurgical therapy was ineffective. Sites of metastases included lung (10 cases), bone (7), brain (4), liver (1), and peritoneum (1). Follow-up ranged from 1 to 107 months after the diagnosis of carcinosarcoma (mean, 34 months; median, 10 months). Mean time to tumor progression was 23 months (range, 1-96 months; median, 18 months). Eighteen patients died of carcinosarcoma from 2 to 107 months (mean, 34 months; median, 9.5 months) after diagnosis. Five-year survival was 41%, and 7-year survival was 14%. Progression and survival were not affected by histologic pattern. Conclusions. Carcinosarcoma of the prostate is an aggressive malignancy, regardless of histologic type.

Original languageEnglish (US)
Pages (from-to)1035-1042
Number of pages8
JournalCancer
Volume76
Issue number6
DOIs
StatePublished - 1995

Fingerprint

Carcinosarcoma
Prostate
Adenocarcinoma
Sarcoma
Survival
Keratin-16
Neoplasm Metastasis
Malignant Fibrous Histiocytoma
Neoplasms
Desmin
Leiomyosarcoma
S100 Proteins
Neoplasm Grading
Fibrosarcoma
Peritoneum
Vimentin
Osteosarcoma
Prostate-Specific Antigen
Androgens
Actins

Keywords

  • carcinoma
  • carcinosarcoma
  • immunohistochemistry
  • pathology
  • prostate
  • prostate specific antigen
  • sarcoma

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Dundore, P. A., Cheville, J. C., Nascimento, A. G., Farrow, G. M., & Bostwick, D. G. (1995). Carcinosarcoma of the prostate: Report of 21 cases. Cancer, 76(6), 1035-1042. https://doi.org/10.1002/1097-0142(19950915)76:6<1035::AID-CNCR2820760618>3.0.CO;2-8

Carcinosarcoma of the prostate : Report of 21 cases. / Dundore, P. A.; Cheville, J. C.; Nascimento, A. G.; Farrow, G. M.; Bostwick, D. G.

In: Cancer, Vol. 76, No. 6, 1995, p. 1035-1042.

Research output: Contribution to journalArticle

Dundore, PA, Cheville, JC, Nascimento, AG, Farrow, GM & Bostwick, DG 1995, 'Carcinosarcoma of the prostate: Report of 21 cases', Cancer, vol. 76, no. 6, pp. 1035-1042. https://doi.org/10.1002/1097-0142(19950915)76:6<1035::AID-CNCR2820760618>3.0.CO;2-8
Dundore, P. A. ; Cheville, J. C. ; Nascimento, A. G. ; Farrow, G. M. ; Bostwick, D. G. / Carcinosarcoma of the prostate : Report of 21 cases. In: Cancer. 1995 ; Vol. 76, No. 6. pp. 1035-1042.
@article{1b8553584e2945549afbb78b174551ce,
title = "Carcinosarcoma of the prostate: Report of 21 cases",
abstract = "Background. Carcinosarcoma of the prostate is an unusual malignancy characterized by adenocarcinoma intimately admixed with sarcoma. Methods. The authors reviewed the clinical and pathologic findings of 21 cases of carcinosarcoma of the prostate from the files of the Mayo Clinic. Results. Patient age ranged from 50 to 89 years (mean, 68 years). Ten patients (48{\%}) had a previous diagnosis of prostatic acinar adenocarcinoma 2-73 months (mean, 33 months) before the diagnosis of carcinosarcoma, 8 of whom had received androgen deprivation therapy and/or radiation therapy in the interim. The Gleason score of adenocarcinoma ranged from 7 to 10 (mean, 9; median, 9). The sarcomas consisted of osteosarcoma (13), leiomyosarcoma (5), fibrosarcoma (1), malignant fibrous histiocytoma (1), and rhabdomyosarcoma (1), and the grade of the sarcoma component ranged from 2 to 4 (mean, 4; median, 4). Adenocarcinoma was the dominant histologic pattern in 7 cases and sarcoma in 14. Immunohistochemical staining revealed cytoplasmic reactivity for prostate specific antigen or keratin in 16 of 16 cases in the adenocarcinoma component. The sarcoma component was positive for vimentin in 16 of 16 cases, actin in 8 of 16 (focal in 2), S-100 protein in 2 of 16, and desmin in 1 of 16. At the time of diagnosis of carcinosarcoma, 11 patients had metastases, including 4 with metastatic adenocarcinoma before the diagnosis of carcinosarcoma. Treatment varied, and nonsurgical therapy was ineffective. Sites of metastases included lung (10 cases), bone (7), brain (4), liver (1), and peritoneum (1). Follow-up ranged from 1 to 107 months after the diagnosis of carcinosarcoma (mean, 34 months; median, 10 months). Mean time to tumor progression was 23 months (range, 1-96 months; median, 18 months). Eighteen patients died of carcinosarcoma from 2 to 107 months (mean, 34 months; median, 9.5 months) after diagnosis. Five-year survival was 41{\%}, and 7-year survival was 14{\%}. Progression and survival were not affected by histologic pattern. Conclusions. Carcinosarcoma of the prostate is an aggressive malignancy, regardless of histologic type.",
keywords = "carcinoma, carcinosarcoma, immunohistochemistry, pathology, prostate, prostate specific antigen, sarcoma",
author = "Dundore, {P. A.} and Cheville, {J. C.} and Nascimento, {A. G.} and Farrow, {G. M.} and Bostwick, {D. G.}",
year = "1995",
doi = "10.1002/1097-0142(19950915)76:6<1035::AID-CNCR2820760618>3.0.CO;2-8",
language = "English (US)",
volume = "76",
pages = "1035--1042",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "6",

}

TY - JOUR

T1 - Carcinosarcoma of the prostate

T2 - Report of 21 cases

AU - Dundore, P. A.

AU - Cheville, J. C.

AU - Nascimento, A. G.

AU - Farrow, G. M.

AU - Bostwick, D. G.

PY - 1995

Y1 - 1995

N2 - Background. Carcinosarcoma of the prostate is an unusual malignancy characterized by adenocarcinoma intimately admixed with sarcoma. Methods. The authors reviewed the clinical and pathologic findings of 21 cases of carcinosarcoma of the prostate from the files of the Mayo Clinic. Results. Patient age ranged from 50 to 89 years (mean, 68 years). Ten patients (48%) had a previous diagnosis of prostatic acinar adenocarcinoma 2-73 months (mean, 33 months) before the diagnosis of carcinosarcoma, 8 of whom had received androgen deprivation therapy and/or radiation therapy in the interim. The Gleason score of adenocarcinoma ranged from 7 to 10 (mean, 9; median, 9). The sarcomas consisted of osteosarcoma (13), leiomyosarcoma (5), fibrosarcoma (1), malignant fibrous histiocytoma (1), and rhabdomyosarcoma (1), and the grade of the sarcoma component ranged from 2 to 4 (mean, 4; median, 4). Adenocarcinoma was the dominant histologic pattern in 7 cases and sarcoma in 14. Immunohistochemical staining revealed cytoplasmic reactivity for prostate specific antigen or keratin in 16 of 16 cases in the adenocarcinoma component. The sarcoma component was positive for vimentin in 16 of 16 cases, actin in 8 of 16 (focal in 2), S-100 protein in 2 of 16, and desmin in 1 of 16. At the time of diagnosis of carcinosarcoma, 11 patients had metastases, including 4 with metastatic adenocarcinoma before the diagnosis of carcinosarcoma. Treatment varied, and nonsurgical therapy was ineffective. Sites of metastases included lung (10 cases), bone (7), brain (4), liver (1), and peritoneum (1). Follow-up ranged from 1 to 107 months after the diagnosis of carcinosarcoma (mean, 34 months; median, 10 months). Mean time to tumor progression was 23 months (range, 1-96 months; median, 18 months). Eighteen patients died of carcinosarcoma from 2 to 107 months (mean, 34 months; median, 9.5 months) after diagnosis. Five-year survival was 41%, and 7-year survival was 14%. Progression and survival were not affected by histologic pattern. Conclusions. Carcinosarcoma of the prostate is an aggressive malignancy, regardless of histologic type.

AB - Background. Carcinosarcoma of the prostate is an unusual malignancy characterized by adenocarcinoma intimately admixed with sarcoma. Methods. The authors reviewed the clinical and pathologic findings of 21 cases of carcinosarcoma of the prostate from the files of the Mayo Clinic. Results. Patient age ranged from 50 to 89 years (mean, 68 years). Ten patients (48%) had a previous diagnosis of prostatic acinar adenocarcinoma 2-73 months (mean, 33 months) before the diagnosis of carcinosarcoma, 8 of whom had received androgen deprivation therapy and/or radiation therapy in the interim. The Gleason score of adenocarcinoma ranged from 7 to 10 (mean, 9; median, 9). The sarcomas consisted of osteosarcoma (13), leiomyosarcoma (5), fibrosarcoma (1), malignant fibrous histiocytoma (1), and rhabdomyosarcoma (1), and the grade of the sarcoma component ranged from 2 to 4 (mean, 4; median, 4). Adenocarcinoma was the dominant histologic pattern in 7 cases and sarcoma in 14. Immunohistochemical staining revealed cytoplasmic reactivity for prostate specific antigen or keratin in 16 of 16 cases in the adenocarcinoma component. The sarcoma component was positive for vimentin in 16 of 16 cases, actin in 8 of 16 (focal in 2), S-100 protein in 2 of 16, and desmin in 1 of 16. At the time of diagnosis of carcinosarcoma, 11 patients had metastases, including 4 with metastatic adenocarcinoma before the diagnosis of carcinosarcoma. Treatment varied, and nonsurgical therapy was ineffective. Sites of metastases included lung (10 cases), bone (7), brain (4), liver (1), and peritoneum (1). Follow-up ranged from 1 to 107 months after the diagnosis of carcinosarcoma (mean, 34 months; median, 10 months). Mean time to tumor progression was 23 months (range, 1-96 months; median, 18 months). Eighteen patients died of carcinosarcoma from 2 to 107 months (mean, 34 months; median, 9.5 months) after diagnosis. Five-year survival was 41%, and 7-year survival was 14%. Progression and survival were not affected by histologic pattern. Conclusions. Carcinosarcoma of the prostate is an aggressive malignancy, regardless of histologic type.

KW - carcinoma

KW - carcinosarcoma

KW - immunohistochemistry

KW - pathology

KW - prostate

KW - prostate specific antigen

KW - sarcoma

UR - http://www.scopus.com/inward/record.url?scp=0029083713&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029083713&partnerID=8YFLogxK

U2 - 10.1002/1097-0142(19950915)76:6<1035::AID-CNCR2820760618>3.0.CO;2-8

DO - 10.1002/1097-0142(19950915)76:6<1035::AID-CNCR2820760618>3.0.CO;2-8

M3 - Article

C2 - 8625205

AN - SCOPUS:0029083713

VL - 76

SP - 1035

EP - 1042

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 6

ER -